ARGX
argenx SE
There isn't enough reported data to score ARGX yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
ARGX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
ARGX's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ARGX PE Valuation
ARGX has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ARGX Forward outlook
There aren't enough analyst estimates for ARGX to show an outlook.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
ARGX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2021 | -$7.99 | +$4.95 |
| Q2 2021 | -$6.52 | +$2.10 |
| Q4 2020 | -$12.94 | -$8.25 |
| Q2 2020 | -$8.62 | -$5.78 |
| Q4 2019 | -$4.69 | -$2.48 |
| Q4 2018 | -$2.21 | -$0.94 |
ARGX lost $7.99 per share over the past year, a bigger loss than the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over ARGX in the latest year-over-year earnings comparison.
ARGX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2021 | $497.3M | +3089% |
| Q2 2021 | $470.4M | +1791% |
| Q4 2020 | $15.6M | -47% |
| Q2 2020 | $24.9M | -49% |
| Q4 2019 | $29.2M | +635% |
| Q2 2019 | $48.4M | +143% |
| Q4 2018 | $4M | -90% |
| Q4 2017 | $40.5M | +275% |
ARGX has the edge over LLY in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2021 | -70% | +403 points |
| Q2 2021 | 20% | +145 points |
| Q4 2020 | -1541% | +39 points |
| Q2 2020 | -900% | -758 points |
| Q4 2019 | -473% | -410 points |
| Q2 2019 | -125% | +20 points |
| Q4 2018 | -1581% | -1475 points |
| Q2 2018 | -142% | -4.6 points |
ARGX's operating margin was −70% last quarter, up 403 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
ARGX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2021 | -$610.4M | -$376.4M |
| Q2 2021 | -$227.5M | -$75.6M |
| Q4 2020 | -$234M | -$128.8M |
| Q2 2020 | -$151.8M | -160% |
| Q4 2019 | -$105.2M | -$75.7M |
| Q2 2019 | $253M | +$283.9M |
| Q4 2018 | -$29.5M | +$11.5M |
| Q4 2017 | -$41M | -$28.2M |
ARGX has burned cash in most quarters: −$1.2B over the past year, against $87M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
ARGX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +437K shares |
| 1 year | +32% | +12.5M shares |
| 3 years | +225% | +35.4M shares |
ARGX has 51M diluted shares, up 32% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2016 | — |
| Q2 2016 | — |
| Q4 2015 | — |
| Q2 2015 | — |
| Q4 2014 | — |
| Q2 2014 | — |
| Q4 2013 | — |
| Q2 2013 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over ARGX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ARGX Net Leverage
ARGX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
ARGX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.4 | Neutral |
| Stochastic | 51.3 | Neutral |
ARGX's weekly RSI is 58 (neutral) and its Stochastic is 51 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ARGX PE vs Healthcare Sector
ARGX has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ARGX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $899.8 | 9.1% above |
| 20 week MA | $921.8 | 6.5% above |
| 50 week MA | $855.0 | 15% above |
| 100 week MA | $759.7 | 29% above |
| 200 week MA | $602.7 | 63% above |
ARGX is in an uptrend: it's above all five of its weekly moving averages, and 63% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
ARGX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $160.8 | $299.5 | +86% |
| 2021 | $299.5 | $350.0 | +17% |
| 2022 | $350.0 | $377.3 | +7.8% |
| 2023 | $377.3 | $380.4 | +0.8% |
| 2024 | $380.4 | $626.3 | +65% |
| 2025 | $626.3 | $844.9 | +35% |
| 2026 YTD | $844.9 | $981.3 | +16% |
ARGX has finished every year since 2020 higher, and it's up 16% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over ARGX on returns for 2026, with the stronger performance.